REBIRTH Mitglieder

Mischak-Weissinger, Eva

Mischak-Weissinger, Eva, Prof. Dr. med.

Dept. Hematology, Hemostasis and Oncology

Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover

Mischak-Weissinger.Eva(at)mh-hannover.

Biography / About

Date of Birth:November, 1962
Function:Head of laboratory of Transplantation Biology

Education:

10/1980 – 06/1987University of Vienna, Medical faculty
11/1987Dr. med. univ. (MD) Universität Wien

Academic appointments and Research posts:

11/1987 – 03/1989Fellow at “2. Chirurgische Universitätsklink” (Herz und Gefäßchirurgie
04/1989 – 04/1992“Fogarty Fellow” at “Laboratory of Genetics”, National Institutes of Health (NIH), National cancer InstituteNCI, Bethesda, MD, USA
04/1992 – 04/1993“Fogarty Visiting Associate” NIH, NCI, Bethesda, MD, USA.
08/1993 – 09/1998Scientist; GSF-Hämatologikum Department of Clinical Hematology, LMU and GSF, München, Germany
12/1997Post-doctoral lecturing qualification (Habilitation) Experimental Hematology Lecturer (Privatdozentin) at “Ludwig-Maximilians-Universität” München, Germany
11/1999 – 09/2002Senior scientist, Hannover Medical School (MHH), Dept. Hematology, Hemostasis, and Oncology Medical School (MHH), Dept
02/2002License to practice medicine (Approbation)
09/2002 – 12/2004“Chief medical officer” (CMO) at mosaiques diagnostics& therapeutics AG
Since 2004Scientific group leader (head of Laboratory of Transplantation Biology”; Hannover Transplantation)
Since 2006Attending physician (“Oberärztin”) Dept. Hematology, Hemostasis, Oncology and Stem Cell Transplantation and head of Laboratory for Transplantation biology

Other professional activities:

2005Nomination as “professor for experimental hematology” (APL)

Awards and Prizes:

2004“Rudolf-Schön Award” for publication in Blood; (2004) 104: 340-349
2007Cooperation Award of Lower-Saxony, 1st prize

Major research interests:

Complications after allogeneic stem cell transplantation like cytomegalovirus reactivations, acute (aGvHE) and chronic graft-versus-host disease (cGvHD), proteomics and imunology

Furthermore:

Gene therapy trials since 2002: Control of acute GvHD using HSV-TK and NGFR-expressing retroviruses to eliminate T-cells in vivo in case of aGvHD.

Selected Publications:

  1. Weissinger EM, Human C, Metzger J, Hambach L, Wolf D, Greinix HT, et al. The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation. Leukemia. 2017;31(3):654-62.
  2. Hage E, Wilkie GS, Linnenweber-Held S, Dhingra A, Suarez NM, Schmidt JJ, Kay-Fedorov, P., Mischak-Weissinger, E., Heim, A., Schwarz, A., Schulz, T. F., Davison, A. J., Ganzenmueller, T. Characterization of human cytomegalovirus genome diversity in immunocompromised hosts by whole genomic sequencing directly from clinical specimens. J Infect Dis. 2017.
  3. Tomic A, Varanasi PR, Golemac M, Malic S, Riese P, Borst EM, Mischak-Weissinger, E., Guzman, C. A., Krmpotic, A., Jonjic, S. Messerle, M.. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. Plos Pathog. 2016;12(12).
  4. Qesari M, Richter A, Ogonek J, Mischak-Weissinger E, Wang XN, Dickinson AM. Cytomegalovirus-Specific T Cells Isolated by IFN-gamma Secretion Assay Do Not Induce Significant Graft-Versus-Host Reactions In Vitro. Transplantation. 2016;100(11):2352-61.
  5. Weissinger EM, Metzger J, Dobbelstein C, Wolff D, Schleuning M, Kuzmina Z, et al. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia. 2014;28(4):842-52.
  6. Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, Apperley, J., Edinger, M., Hauser, A., Mischak-Weissinger, E., Dickinson, A. M., Lowdell, M. W. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy. 2014;16(3):289-97.
  7. Borchers S, Ogonek J, Varanasi PR, Tischer S, Bremm M, Eiz-Vesper B, Koehl, U., Weissinger, E. M. Multimer monitoring of CMV-specific T cells in research and in clinical applications. Diagn Micr Infec Dis. 2014;78(3):201-12.
  8. Velaga S, Ukena SN, Hopting M, Ivanyi P, Borchers S, Mischak-Weissinger EM, et al. Reconstitution and Phenotype of Tregs in CMV Reactivating Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. Immunol Invest. 2013;42(1):18-35.
  9. Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, Verboom, M., Immenschuh, S., Heim, A., Borchers, S., Mischak-Weissinger, E., Blasczyk, R., Maecker-Kolhoff, B.Eiz-Vesper, B.. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant. 2013;19(10):1480-92.
  10. Prinz I, Thamm K, Port M, Weissinger EM, Stadler M, Gabaev I, et al. Donor Vδ1(+) γδ T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL. Experimental Hematology & Oncology. 2013;2:14-.
  11. Bunse CE, Borchers S, Varanasi PR, Tischer S, Figueiredo C, Immenschuh S, Kalinke, U., Kohl, U., Goudeva, L., Maecker-Kolhoff, B., Ganser, A., Blasczyk, R., Weissinger, E. M., Eiz-Vesper, B.. Impaired Functionality of Antiviral T Cells in G-CSF Mobilized Stem Cell Donors: Implications for the Selection of CTL Donor. Plos One. 2013;8(12).
  12. Borchers S, Weissinger EM, Pabst B, Ganzenmueller T, Dammann E, Luther S, et al. Expansion of recipient-derived antiviral T cells may influence donor chimerism after allogeneic stem cell transplantation. Transpl Infect Dis. 2013;15(6):627-33.


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden